Gastroesophageal adenocarcinoma
diseaseOn this page
Summary
Gastroesophageal adenocarcinoma (MONDO:0850130) is a disease and 33 clinical trials. Top therapeutic interventions include zanidatamab, cabazitaxel, and cisplatin. A subtype of adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 33
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | gastroesophageal adenocarcinoma |
| Mondo ID | MONDO:0850130 |
| DOID | DOID:0080375 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › gastroesophageal adenocarcinoma
Related subtypes (63): epididymal adenocarcinoma, rete testis adenocarcinoma, seminal vesicle adenocarcinoma, ethmoid sinus adenocarcinoma, lacrimal gland adenocarcinoma, papillary adenocarcinoma, fallopian tube adenocarcinoma, bladder adenocarcinoma, ovarian adenocarcinoma, trabecular adenocarcinoma, middle ear adenocarcinoma, bile duct adenocarcinoma, granular cell carcinoma, small intestine adenocarcinoma, urethra adenocarcinoma, villous adenocarcinoma, thymus gland adenocarcinoma, nasal cavity adenocarcinoma, ureter adenocarcinoma, adenocarcinoma in situ, gastroesophageal junction adenocarcinoma, maxillary sinus adenocarcinoma, mucinous adenocarcinoma, acinar cell carcinoma, adenoid cystic carcinoma, breast adenocarcinoma, clear cell adenocarcinoma, colorectal adenocarcinoma, endometrioid adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, lung adenocarcinoma, prostate adenocarcinoma, renal cell carcinoma, signet ring cell carcinoma, cervical adenocarcinoma, serous adenocarcinoma, endometrium adenocarcinoma, sweat gland carcinoma, cystadenocarcinoma, tubular adenocarcinoma, mesonephric adenocarcinoma, scirrhous adenocarcinoma, pancreatic adenocarcinoma, follicular variant thyroid gland papillary carcinoma, gallbladder adenocarcinoma, hepatoid adenocarcinoma, intestinal type adenocarcinoma, micropapillary serous carcinoma, minor salivary gland adenocarcinoma, poorly differentiated thyroid gland carcinoma, salivary gland basal cell adenocarcinoma, submandibular gland adenocarcinoma, sebaceous adenocarcinoma, hepatocellular carcinoma, parathyroid gland carcinoma, pituitary adenocarcinoma, vaginal adenocarcinoma, Paget disease, diffuse type adenocarcinoma, vulvar adenocarcinoma, thyroid gland adenocarcinoma, adenoacanthoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 33.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 15 |
| PHASE1/PHASE2 | 8 |
| PHASE1 | 7 |
| PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05152147 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers |
| NCT04021108 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) |
| NCT05403242 | PHASE1/PHASE2 | RECRUITING | RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2 |
| NCT05986227 | PHASE1/PHASE2 | NOT_YET_RECRUITING | The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): |
| NCT06043427 | PHASE2 | RECRUITING | Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma |
| NCT06245356 | PHASE2 | RECRUITING | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer |
| NCT06445972 | PHASE1/PHASE2 | RECRUITING | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) |
| NCT06469944 | PHASE1/PHASE2 | RECRUITING | Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) |
| NCT06767800 | PHASE2 | RECRUITING | A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
| NCT06921837 | PHASE1/PHASE2 | RECRUITING | A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer |
| NCT06985602 | PHASE2 | RECRUITING | Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ |
| NCT07069712 | PHASE2 | RECRUITING | A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma |
| NCT07176312 | PHASE2 | RECRUITING | Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients |
| NCT07266025 | PHASE2 | NOT_YET_RECRUITING | Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study |
| NCT07282912 | PHASE2 | RECRUITING | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels |
| NCT07290985 | PHASE2 | NOT_YET_RECRUITING | AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas |
| NCT07529808 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma |
| NCT07554521 | PHASE2 | RECRUITING | A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States |
| NCT00073502 | PHASE2 | COMPLETED | Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer |
| NCT01045421 | PHASE1/PHASE2 | COMPLETED | Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies |
| NCT01182610 | PHASE2 | TERMINATED | Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma |
| NCT01757171 | PHASE2 | COMPLETED | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma |
| NCT03639714 | PHASE1/PHASE2 | COMPLETED | A Study of a Personalized Neoantigen Cancer Vaccine |
| NCT05299476 | PHASE2 | COMPLETED | CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA |
| NCT05029882 | PHASE1 | ACTIVE_NOT_RECRUITING | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab |
| NCT05733689 | PHASE1 | RECRUITING | Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) |
| NCT06529822 | PHASE1 | RECRUITING | Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease |
| NCT07544589 | PHASE1 | RECRUITING | A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers |
| NCT02551055 | PHASE1 | TERMINATED | MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma |
| NCT04602117 | PHASE1 | WITHDRAWN | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer |
| NCT05977322 | PHASE1 | TERMINATED | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. |
| NCT04712721 | EARLY_PHASE1 | TERMINATED | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. |
| NCT03794128 | Not specified | COMPLETED | A Study of Personalized Neoantigen Cancer Vaccines |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ZANIDATAMAB | 4 | 4 |
| CABAZITAXEL | 4 | 1 |
| CISPLATIN | 4 | 1 |
| LEVOLEUCOVORIN | 4 | 1 |
| PANITUMUMAB | 4 | 1 |
| TIPIRACIL | 4 | 1 |
| TISLELIZUMAB | 4 | 1 |
| TRIFLURIDINE | 4 | 1 |
| ALISERTIB | 3 | 2 |
| BENMELSTOBART | 3 | 1 |
| PATRITUMAB DERUXTECAN | 3 | 1 |
| RILVEGOSTOMIG | 3 | 1 |
| SACITUZUMAB TIRUMOTECAN | 3 | 1 |
| MIVAVOTINIB | 2 | 2 |
| HILTONOL | 2 | 1 |
| LUTADENOVEC AUTOGENE | 2 | 1 |
| OSI-7904 | 2 | 1 |
| SAPECMERAN AUTOGENE | 2 | 1 |
| SERABELISIB | 2 | 1 |